- CITATIONS: 1
|Application ||IHC-P, DB, E|
|Calculated MW||71597 Da|
|Other Names||Wee1-like protein kinase, WEE1hu, Wee1A kinase, WEE1|
|Target/Specificity||This Wee1 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S123 of human Wee1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-Wee1(S123) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.|
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.
Dai, X., et al., J. Invest. Dermatol. 122(6):1356-1364 (2004).
Watanabe, N., et al., Proc. Natl. Acad. Sci. U.S.A. 101(13):4419-4424 (2004).
Yoshida, T., et al., Ann. Oncol. 15(2):252-256 (2004).
Kawasaki, H., et al., Oncogene 22(44):6839-6844 (2003).
Yuan, H., et al., J. Virol. 77(3):2063-2070 (2003).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.